BrainSight AI, a Bengaluru-based deep-tech neuroscience startup, has raised Pre-series A funding with US$5 million led by IAN Alpha Fund, with participation from IvyCap Ventures, Silver Needle, apart from existing investors. The funding is a significant milestone in BrainSightAI’s mission to revolutionize the diagnosis and treatment of complex brain disorders through its innovative neuroinformatics platform, VoxelBox. Currently, BrainSightAI collaborates with over 40 leading hospitals across India, particularly in neurosurgery and radiology departments, focusing on brain tumor cases. The company is now expanding its solutions to neurological and psychiatric disorders, paving the way for a more holistic approach to brain care.
The funds from this round will be strategically utilized to expand BrainSightAI’s presence in India, increasing its reach in Tier 1 cities and extending to Tier 2 cities. The company also plans to pursue FDA certification, opening access to the US and allied markets. Additionally, the company is gearing up to explore opportunities in Africa and Southeast Asia, based on distributor interest. The funds will also support R&D for a caregiver-focused app, aimed at empowering families of patients with brain disorders.
Founded in 2019, the company is the brainchild of Laina Emmanuel, CEO, and Dr. Rimjhim Agrawal, CTO. Laina, an ISB graduate with over 20 years of experience in healthcare and technology, and Rimjhim, a NIMHANS PhD specializing in machine learning for neurological disorders, met during the Entrepreneur First program. Sharing a vision to democratize advanced brain care, they built BrainSightAI to bridge the gap between research and real-world applications.
Laina Emmanuel, Co-founder & CEO of BrainSightAI, said, “We are very excited by the potential of connectomics to advance personalized brain care for patients and I believe in the long run, for everybody. We are excited to bring on board such stellar investors who believe in our mission, and will help us build for the world from India.”
Priyank Garg, Managing Partner, IAN Alpha Fund, said, “BrainSightAI’s mission to democratize access to personalized brain care is inspiring, and the technology they’ve built is a fundamental innovation in brain physiology. The connectomics platform, VoxelBox, has the potential to transform the way brain disorders are diagnosed and treated for all humanity. At IAN, we are thrilled to support such a purpose-driven company that combines deep-tech innovation with impactful healthcare solutions.”
BrainSightAI is at the forefront of understanding how the physiology of the brain correlates to its functions by mapping macro-scale neural connections in the brain, to enable precise diagnosis and prognosis of neuro-oncological and neuropsychiatric disorders. Traditionally available only at leading global research institutions like Harvard and Stanford, the platform makes this cutting-edge technology accessible to hospitals and patients worldwide.
